Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Alnylam Pharmaceuticals after the company received a positive opinion in Europe for ALN-TTRsc02 orphan designation to treat ATTR amyloidosis. The analyst finds the recommendation encouraging, noting that ALN-TTRsc02 will advance into a Phase III program by the end of 2018. He remains confident in broad patisiran approval in ATTR amyloidosis by the August 11 FDA action date and expects European approval in the second half of 2018. Tenthoff keeps a $182 price target on Alnylam shares.